Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03336983CT.gov Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients | — | Completed | — | — | — |
NCT02721433CT.gov 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases | — | Completed | — | — | — |
NCT01205646CT.gov PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00558272CT.gov Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease | — | Completed | — | — | — |
NCT00365105CT.gov Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer | — | Completed | — | — | — |
NCT00268476CT.gov Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | — | Active Not Recruiting | — | — | — |
NCT00081159CT.gov Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases | — | Completed | — | — | — |
NCT00072930CT.gov MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer | — | Completed | — | — | — |
NCT00193856CT.gov RADAR Trial - Randomised Androgen Deprivation and Radiotherapy | — | Completed | — | — | — |
NCT00058188CT.gov Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation | — | Terminated | — | — | — |
Show 2 more trialsShow fewer
NCT00039104CT.gov Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00181558CT.gov Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Zoledronate (this asset) | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Approved | BB · 69 |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BBB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BBB |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BB |
| Goserelin | Bayer | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Flutamide | VA Office of Research and Development | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Zoledronate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Carcinoma In The Bone | — | P4 | BBB · 76 |
| Osteoporosis | — | P4 | BBB · 73 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Zoledronate in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/zoledronate-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →